2. Search Result
Search Result
Results for "

gastrointestinal (GI)

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

2

Inhibitory Antibodies

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99643
    Ginisortamab

    UCB6114

    		 Dan family Cancer
    Ginisortamab (UCB6114) is a fully human IgG4P anti Gremlin-1 monoclonal antibody, with mean IC50 values of 8.2 nM and 9 nM against human and mouse gremlin-1, respectivly. Ginisortamab inhibits gremlin-1 antagonism of BMP signaling pathways. Ginisortamab has the potential for the research of gastrointestinal (GI) tumors .
    Ginisortamab
  • HY-B0189B
    Mosapride citrate dihydrate
    4 Publications Verification

    TAK-370 citrate dihydrate; AS-4370 citrate dihydrate

    		 5-HT Receptor Potassium Channel Cytochrome P450 Metabolic Disease Cancer
    Mosapride (TAK-370) citrate dehydrate is a gastroprokinetic agent with 5-hydroxytryptamine4 receptor agonist activity and has been widely used in the research of a variety of gastrointestinal disorders. Mosapride citrate dihydrate potently inhibits Kv4.3 in a concentration-dependent manner with IC50 values of 15.2 μM . Mosapride citrate dihydrateselectively stimulates upper GI motility in vivo .
    Mosapride citrate dihydrate
  • HY-16729A
    Relenopride hydrochloride

    YKP10811 hydrochloride

    		 5-HT Receptor Inflammation/Immunology
    Relenopride (YKP10811) hydrochloride is a specific and selective 5-HT4 receptor agonist (Ki=4.96 nM). Relenopride hydrochloride has 120-fold and 6-fold lower affinity, respectively, for 5-HT2A (Ki=600 nM) and 5-HT2B receptors (Ki=31 nM) than for 5-HT4. Relenopride hydrochloride increases gastrointestinal (GI) motility .
    Relenopride hydrochloride
  • HY-B0194
    Tizanidine

    		Adrenergic Receptor Neurological Disease Endocrinology Cancer
    Tizanidine is an orally active, imidazoline central α2-adrenoceptor agonist (IC50 = 6.9 nmol), which can be used to manage spasticity secondary to conditions such as multiple sclerosis (MS), stroke, and spinal cord injury (SCI). Tizanidine is a centrally acting skeletal muscle relaxant. Tizanidine reduces the release of the excitatory amino acids glutamate and aspartate from the presynaptic terminal of spinal interneurons. Tizanidine reduces tonic stretch reflexes and polysynaptic reflex activity in spinal transected cat model. Tizanidine can decrease blood pressure and heart rate in animal models. Tizanidine possesses antinociceptive activity and inhibits gastrointestinal (GI) transit .
    Tizanidine
  • HY-177063
    IL-6-IN-2

    		Interleukin Related Others
    IL-6-IN-2 (Compound 15) is an inhibitor of the IL-6/IL-6R protein interaction. The ∆G binding energy of IL-6-IN-2 is −36.50 kcal/mol. Contributions of Lys66, Phe74, Gln175, Ser176, and Arg179 to IL-6 binding are −1.10, −8.68, −6.91, −3.69, and −1.72 kcal/mol, respectively. IL-6-IN-2 exhibits low gastrointestinal (GI) absorption .
    IL-6-IN-2
  • HY-P99643A
    Ginisortamab (Mouse IgG1)

    		Dan family Cancer
    Ginisortamab (Mouse IgG1) is the anti-Gremlin-1 monoclonal antibody with mouse IgG1. Ginisortamab (Mouse IgG1) can be used in research of gastrointestinal (GI) tumors .
    Ginisortamab (Mouse IgG1)
  • HY-101122
    LX2761

    		SGLT Metabolic Disease
    LX2761 is chemically stable and potent inhibitor against sodium-dependent glucose cotransporter 1 (SGLT1) and SGLT2 in vitro with IC50s of 2.2 nM and 2.7nM for hSGLT1 and hSGLT2, but displays specific SGLT1 inhibition in the gastrointestinal (GI) tract .
    LX2761
  • HY-14153AS
    Tegaserod-13C,d3 maleate

    SDZ-HTF-919-13C,d3; HTF-919-13C,d3

    		 Isotope-Labeled Compounds 5-HT Receptor Neurological Disease Metabolic Disease
    Tegaserod- 13C,d3 (maleate) is the 13C- and deuterium labeled Tegaserod (maleate). Tegaserod maleate is a selective 5-HT4 receptor partial agonist and a 5-HT2B receptor antagonist. Tegaserod maleate exhibits a promotile effect throughout the gastrointestinal (GI) tract .
    Tegaserod-13C,d3 maleate
  • HY-162373
    α-Amylase/α-Glucosidase-IN-10

    		Amylases Glycosidase P-glycoprotein Metabolic Disease
    α-Amylase/α-Glucosidase-IN-10 (compound 5d) is an α-amylase and α-glucosidase inhibitor (IC50: 30.39 μM and 65.1 μM) with potential diabetes inhibitory effects. α-Amylase/α-Glucosidase-IN-10 exhibits high gastrointestinal (GI) absorption in ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) prediction. While α-Amylase/α-Glucosidase-IN-10 acts as a substrate for P-gp and does not cross the blood-brain barrier (BBB), there may be a risk of central nervous system side effects .
    α-Amylase/α-Glucosidase-IN-10
  • HY-B0194R
    Tizanidine (Standard)

    		Reference Standards Adrenergic Receptor Neurological Disease Endocrinology Cancer
    Tizanidine (Standard) is the analytical standard of Tizanidine. This product is intended for research and analytical applications. Tizanidine is an orally active, imidazoline central α2-adrenoceptor agonist (IC50 = 6.9 nmol), which can be used to manage spasticity secondary to conditions such as multiple sclerosis (MS), stroke, and spinal cord injury (SCI). Tizanidine is a centrally acting skeletal muscle relaxant. Tizanidine reduces the release of the excitatory amino acids glutamate and aspartate from the presynaptic terminal of spinal interneurons. Tizanidine reduces tonic stretch reflexes and polysynaptic reflex activity in spinal transected cat model. Tizanidine can decrease blood pressure and heart rate in animal models. Tizanidine possesses antinociceptive activity and inhibits gastrointestinal (GI) transit .
    Tizanidine (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: